A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT02639182. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.
Study identification
- NCT ID
- NCT02639182
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 133 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 3, 2016 (Actual)
- Primary completion
- Oct 2, 2020 (Actual)
- Completion
- Oct 2, 2020 (Actual)
- Last update posted
- Nov 18, 2024
2016 – 2020
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site US01026 | Tucson | Arizona | 85719 | — |
| Site US01008 | La Jolla | California | 92093 | — |
| Site US01007 | Los Angeles | California | 90033 | — |
| Site US01020 | Los Angeles | California | 90095 | — |
| Site US01019 | Palo Alto | California | 94305 | — |
| Site US01010 | Atlanta | Georgia | 30322 | — |
| Site US01023 | Baltimore | Maryland | 21201 | — |
| Site US01002 | Boston | Massachusetts | 02215 | — |
| Site US01004 | Ann Arbor | Michigan | 48109 | — |
| Site US01013 | Detroit | Michigan | 48202 | — |
| Site US01012 | Omaha | Nebraska | 68130 | — |
| Site US01006 | Buffalo | New York | 14263 | — |
| Site US01022 | Durham | North Carolina | 27710 | — |
| Site US01017 | Portland | Oregon | 97213 | — |
| Site US01021 | Pittsburgh | Pennsylvania | 15232 | — |
| Site US01011 | Charleston | South Carolina | 29425 | — |
| Site US01003 | Houston | Texas | 77030 | — |
| Site US01014 | Temple | Texas | 76508 | — |
| Site US01001 | Seattle | Washington | 98109 | — |
| Site US01009 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02639182, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2024 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02639182 live on ClinicalTrials.gov.